Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A9 | P06702 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788233 | 0.84 | GABRA1 (0.38) | ALOX15USP2ALDH1A1GAAPKM | |
| SCHEMBL17703485 | 0.79 | S100A9 (0.43) | S100A9ABCB11ALDH1A1HPGDHSD17B10 | |
| SCHEMBL16248198 | 0.77 | S100A9 (0.42) | S100A9ABCB11ALOX15ALDH1A1HPGD | |
| SCHEMBL13933049 | 0.71 | TRPA1 (0.37) | — | |
| SCHEMBL24925495 | 0.70 | KDM4E (0.40) | ALDH1A1GAAHPGD | |
| SCHEMBL19819833 | 0.68 | S100A9 (0.46) | S100A9ABCB11ALDH1A1 | |
| SCHEMBL6673904 | 0.65 | ABCB11 (0.47) | ABCB11ALOX15USP2ALDH1A1GAA | |
| SCHEMBL20888047 | 0.64 | NUDT1 (0.35) | ALDH1A1HPGD | |
| SCHEMBL18266295 | 0.64 | NOS3 (0.35) | — | |
| SCHEMBL12806682 | 0.64 | AGBL2 (0.50) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | S100A9 1/4885ABCB11 3937/4885ALOX15 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.